- Home
- CMMB vs PULM Comparison
CMMB vs PULM Comparison
Compare CMMB & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- PULM
- Stock Information
- Founded
- CMMB 2004
- PULM 2003
- Country
- CMMB Israel
- PULM United States
- Employees
- CMMB N/A
- PULM N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- PULM Health Care
- Exchange
- CMMB Nasdaq
- PULM Nasdaq
- Market Cap
- CMMB 22.0M
- PULM 20.5M
- IPO Year
- CMMB N/A
- PULM N/A
- Fundamental
- Price
- CMMB $0.95
- PULM $5.00
- Analyst Decision
- CMMB Strong Buy
- PULM
- Analyst Count
- CMMB 2
- PULM 0
- Target Price
- CMMB $8.50
- PULM N/A
- AVG Volume (30 Days)
- CMMB 125.0K
- PULM 9.8K
- Earning Date
- CMMB 08-20-2025
- PULM 08-06-2025
- Dividend Yield
- CMMB N/A
- PULM N/A
- EPS Growth
- CMMB N/A
- PULM N/A
- EPS
- CMMB N/A
- PULM N/A
- Revenue
- CMMB N/A
- PULM $369,000.00
- Revenue This Year
- CMMB N/A
- PULM N/A
- Revenue Next Year
- CMMB N/A
- PULM $134.88
- P/E Ratio
- CMMB N/A
- PULM N/A
- Revenue Growth
- CMMB N/A
- PULM N/A
- 52 Week Low
- CMMB $0.87
- PULM $1.78
- 52 Week High
- CMMB $2.55
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- CMMB 17.79
- PULM 30.61
- Support Level
- CMMB $0.87
- PULM $4.91
- Resistance Level
- CMMB $1.01
- PULM $5.44
- Average True Range (ATR)
- CMMB 0.06
- PULM 0.29
- MACD
- CMMB -0.01
- PULM -0.01
- Stochastic Oscillator
- CMMB 23.78
- PULM 7.28
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).